Discuss This Drug

venetoclax

CHEBI:CHEBI_133021

Definition

A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.

Chemical Information

Molecular Formula
C45H50ClN7O7S
Molecular Mass
868.442
Charge
0
SMILES
C1N(CCN(C1)C2=CC=C(C(NS(C3=CC=C(C(=C3)[N+](=O)[O-])NCC4CCOCC4)(=O)=O)=O)C(=C2)OC=5C=C6C(=NC5)NC=C6)CC=7CCC(CC7C=8C=CC(=CC8)Cl)(C)C
InChI
InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
InChIKey
LQBVNQSMGBZMKD-UHFFFAOYSA-N

Alternative Names

  • 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide
  • ABT 199
  • ABT-199
  • ABT199
  • GDC 0199
  • Venclexta
  • venetoclax

Treatment Applications

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

core#notation
CHEBI:133021
DRON_00010000
1747556
oboInOwl#hasDbXref
Wikipedia:Venetoclax

Additional References

Wikipedia:Venetoclax

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

core#notation
CHEBI:133021
rxcui
1747580
active_ingredient_strength
1 kg/kg
pharm_class_moa
P-Glycoprotein Inhibitors [MoA]
pharm_class
Increased Cellular Death [PE]
nui
N0000009176
package_marketing_start_date
29-MAR-19
manufacturer_name
AbbVie Inc.
package_description
14363 TABLET, FILM COATED in 1 DRUM (68543-0576-9)
unii
N54AIC43PW
spl_set_id
b118a40d-6b56-cee3-10f6-ded821a97018
pharm_class_epc
BCL-2 Inhibitor [EPC]
pharm_class_pe
Increased Cellular Death [PE]
active_ingredient_name
VENETOCLAX
package_ndc
68513-0576-9
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
rdf-schema#range
https://w3id.org/def/predibionto#has_drug_113895
oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
1747556
oboInOwl#hasDbXref
Wikipedia:Venetoclax
oboInOwl#id
CHEBI:133021
brand_name
Venclexta
brand_name_base
Venclexta
dosage_form
POWDER
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT
listing_expiration_date
20241231
route
ORAL
marketing_start_date
20231129
labeler_name
AbbVie Biotechnology LTD
generic_name
Venetoclax
product_ndc
68543-0576
application_number
NDA208573
spl_id
177c4b18-321a-46f0-9695-8c81719acd01
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_68495
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
has_treatment
http://purl.obolibrary.org/obo/DOID_0081412
owl#annotatedSource
t100692
owl#someValuesFrom
t3003361
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect1981